SCHEDULE: Eventide Asset Management Reports 2.0% Celldex Stake

Eventide Asset Management and associated individuals have reported a 2.0% beneficial ownership stake in Celldex Therapeutics, Inc. as of June 30, 2025.

Summary

• Eventide Asset Management, LLC, Finny Kuruvilla, M.D., Ph.D., and Robin C. John collectively reported beneficial ownership of 1,356,186 shares of Celldex Therapeutics, Inc. Common Stock.
• This ownership represents 2.0% of the outstanding class of Celldex Therapeutics, Inc. Common Stock.
• Eventide Asset Management, LLC holds sole voting and dispositive power over all 1,356,186 shares.
• Finny Kuruvilla, M.D., Ph.D. and Robin C. John hold shared voting and dispositive power over the same 1,356,186 shares.
• The shares were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of the issuer.

Sentiment

Score: 6

Explanation: The filing is neutral to slightly positive. It indicates continued institutional interest in Celldex Therapeutics, Inc., which is generally a positive signal. However, the 2.0% stake is not a highly significant position, and the filing itself does not contain new operational or financial information about the company.

Positives

• The filing indicates continued institutional interest in Celldex Therapeutics, Inc. by Eventide Asset Management, LLC and its principals.
• The acquisition of shares is stated to be in the ordinary course of business, suggesting a passive investment strategy rather than an activist one.

Industry Context

This filing is a routine disclosure of beneficial ownership by an institutional investor in the biotechnology sector. Such filings provide transparency regarding significant holdings by investment firms, which can signal confidence in a company's long-term prospects, though a 2.0% stake is not typically considered a major position.

Stakeholder Impact

• Shareholders may view the continued institutional ownership as a minor positive, indicating a degree of confidence from professional investors.

Key Dates

Recommendation

This Schedule 13G filing merely discloses beneficial ownership by an institutional investor and does not contain financial performance data, strategic updates, or other information typically used to formulate a buy or sell recommendation. The 2.0% stake is not significant enough to imply a strong endorsement or concern, thus a 'hold' recommendation is appropriate as the filing provides no new fundamental information to alter an existing investment thesis.

Keywords

Celldex Therapeutics, Eventide Asset Management, beneficial ownership, Schedule 13G, common stock, institutional investment, biotechnology